Latest News about Beckley Psytech
Recent news which mentions Beckley Psytech
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
November 13, 2024
From Benzinga
Beckley Psytech Doses First Patients With Psilocin In Trial For Treatment Of Major Depression Disorder
June 20, 2024
Tickers
NEWS
From Benzinga
UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage
April 05, 2023
From Benzinga
From Benzinga
Beyond Magic Mushrooms: Positive Clinical Trial For Treatment-Resistant Depression & Alcoholism
November 16, 2022
From Benzinga
Psychedelics M&A: Beckley Psytech Acquires Eleusis Therapeutics, Strengthening Drug Pipeline And R&D Team
October 24, 2022
From Benzinga
Palo Santo Closes $50M Psychedelic Therapeutics Investment Fund
October 12, 2022
From Benzinga
Beckley Psytech Begins Training Therapists For Phase 2 Trial With Toad Venom, 5-MeO-DMT
January 24, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.